These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15279838)

  • 1. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
    Yamazaki Y; Fujita K; Nakayama K; Suzuki A; Nakamura K; Yamazaki H; Kamataki T
    Mutat Res; 2004 Aug; 562(1-2):151-62. PubMed ID: 15279838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108.
    Miyazaki M; Sugawara E; Yoshimura T; Yamazaki H; Kamataki T
    Mutat Res; 2005 Mar; 581(1-2):165-71. PubMed ID: 15725615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):339-46. PubMed ID: 11774366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines.
    Suzuki A; Kushida H; Iwata H; Watanabe M; Nohmi T; Fujita K; Gonzalez FJ; Kamataki T
    Cancer Res; 1998 May; 58(9):1833-8. PubMed ID: 9581821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
    Shimada T; Hayes CL; Yamazaki H; Amin S; Hecht SS; Guengerich FP; Sutter TR
    Cancer Res; 1996 Jul; 56(13):2979-84. PubMed ID: 8674051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450.
    Muto S; Fujita K; Yamazaki Y; Kamataki T
    Mutat Res; 2001 Aug; 479(1-2):197-206. PubMed ID: 11470492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1, and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase.
    Oda Y; Aryal P; Terashita T; Gillam EM; Guengerich FP; Shimada T
    Mutat Res; 2001 May; 492(1-2):81-90. PubMed ID: 11377247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
    Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
    Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
    Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
    Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5.
    Kang IH; Kim HJ; Oh H; Park YI; Dong MS
    Mutat Res; 2004 Jan; 545(1-2):37-47. PubMed ID: 14698415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108.
    Kushida H; Fujita K; Suzuki A; Yamada M; Nohmi T; Kamataki T
    Mutat Res; 2000 Nov; 471(1-2):135-43. PubMed ID: 11080669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxic activation of 2-phenylbenzotriazole-type compounds by human cytochrome P4501A1 and N-acetyltransferase expressed in Salmonella typhimurium umu strains.
    Oda Y; Watanabe T; Terao Y; Nukaya H; Wakabayashi K
    Mutat Res; 2008 Jun; 654(1):52-7. PubMed ID: 18562244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
    Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
    Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new genotoxicity test system with Salmonella typhimurium OY1001/1A2 expressing human CYP1A2 and NADPH-P450 reductase.
    Aryal P; Yoshikawa K; Terashita T; Guengerich FP; Shimada T; Oda Y
    Mutat Res; 1999 Jun; 442(2):113-20. PubMed ID: 10393280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
    Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
    Carcinogenesis; 2000 Jun; 21(6):1227-32. PubMed ID: 10837014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of genetically engineered Salmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-cytochrome P450 reductase and bacterial O-acetyltransferase in SOS/umu assay.
    Aryal P; Terashita T; Guengerich FP; Shimada T; Oda Y
    Environ Mol Mutagen; 2000; 36(2):121-6. PubMed ID: 11013410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotoxic activation of the environmental pollutant 3,6-dinitrobenzo[e]pyrene in Salmonella typhimurium umu strains expressing human cytochrome P450 and N-acetyltransferase.
    Oda Y; Hirayama T; Watanabe T
    Toxicol Lett; 2009 Aug; 188(3):258-62. PubMed ID: 19393727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin.
    Takahashi E; Fujita K; Kamataki T; Arimoto-Kobayashi S; Okamoto K; Negishi T
    Mutat Res; 2002 Oct; 508(1-2):147-56. PubMed ID: 12379470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.